Reduction intrapulmonary shunts and plasma levels of vascular endothelial growth factor and TNF (Rosuvastatin alleviates experimental hepatopulmonary syndrome through blockade of pulmonary inflammatory angiogenesis via TNF/NF-κB and VEGF/Rho-associated A kinase pathways down-regulation). This evidence concerns the gene NFKB1 and hepatopulmonary syndrome.